drugset / Trial / NCT01349816
PT003 MDI Dose Confirmation Study
RandomizedCrossoverQuadruple-blindTreatment
Summary
The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Timeline
- Start
- 2011-06
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Formoterol | Other / unclassified | 7.2 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 9.6 ug | Inhaled |
| Subject | Glycopyrrolate | Small molecule | 9 ug | Inhaled |
| Subject | Glycopyrrolate | Small molecule | 18 ug | Inhaled |
| Subject | Glycopyrrolate | Small molecule | 36 ug | Inhaled |